Posted by Michael Wonder on 04 Oct 2023
US Patent Office won't review two Novo Nordisk patents for Wegovy, Ozempic
2 October 2023 - A US Patent Office tribunal on Monday rejected challenges to two key patents owned by Novo Nordisk covering the active ingredient in its weight loss and diabetes drugs Wegovy and Ozempic brought by a generic drug maker that is hoping to sell generic versions of the blockbuster medications.
The office's Patent Trial and Appeal Board denied the requests by Mylan Pharmaceuticals, which is owned by Viatris, to review the validity of the Wegovy and Ozempic patents. Mylan had argued that the patents were obvious based on the anti-diabetes medication liraglutide and thus should be invalidated.
